Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DYNAMIC-Pancreas
ACTRN12618000335291Phase 3Terminated
- Sponsor
- Australasian Gastro-Intestinal Trials Group
- Start
- Mar 2019
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of FOLFIRINOX, gemcitabine + capecitabine and gemcitabine + nab-paclitaxel in pancreatic adenocarcinoma (PDAC) and pancreatic cancer (PC) (3 cohorts), sponsored by Australasian Gastro-Intestinal Trials Group. Primary endpoints: 2-year recurrence-free survival and ctDNA positivity compared with CA 19-9. Started Mar 2019; status: terminated.
02
Drugs
FOLFIRINOXgemcitabine + capecitabinegemcitabine + nab-paclitaxel
03
Conditions
pancreatic adenocarcinoma (PDAC)pancreatic cancer (PC)
Beyond the preview
Go deeper on ACTRN12618000335291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618000335291.